Clinical Guides
Strongyloidiasis
A clinically focused clinical guide to recognising, diagnosing and treating Strongyloides stercoralis infection, with particular emphasis on preventing fatal hyperinfection during immunosuppression.
MedNext Academy | 14 min read
Strongyloidiasis
A clinically focused clinical guide to recognising, diagnosing and treating Strongyloides stercoralis infection, with particular emphasis on preventing fatal hyperinfection during immunosuppression.
Summary
Strongyloidiasis is infection with the soil-transmitted nematode Strongyloides stercoralis. Infective filariform larvae penetrate skin, migrate through the circulation and lungs, are swallowed, and mature into parthenogenetic adult females in the small intestine. Unlike common intestinal helminths, rhabditiform offspring can become infective before leaving the host. This autoinfection cycle permits a low-grade infection to persist for decades and explains why remote residence in an endemic area remains clinically relevant.
Most chronic infection is asymptomatic or causes intermittent abdominal, respiratory or cutaneous symptoms. Larva currens, a rapidly advancing serpiginous urticarial eruption often affecting buttocks or thighs, is particularly suggestive. Peripheral eosinophilia supports suspicion in uncomplicated disease but is neither sufficiently sensitive nor specific to rule infection in or out. Eosinophilia may disappear in severe disease.
The crucial clinical hazard is accelerated autoinfection after corticosteroids or other impairment of cell-mediated immunity. Hyperinfection increases larvae along the usual gastrointestinal-pulmonary route; dissemination identifies larvae in organs outside that route. Both may produce enterocolitis, respiratory failure, Gram-negative bacteraemia or meningitis and can be fatal. Ask about lifetime exposure before immunosuppression, test with an appropriate combination of serology and sensitive parasitology, and treat proven infection. Ivermectin is preferred for uncomplicated disease. Suspected hyperinfection is an emergency requiring daily therapy, microbiological investigation, supportive care and specialist coordination. WHO's 2024 recommendation for annual community ivermectin in eligible endemic settings is population guidance, not a substitute for individual diagnosis and treatment.
How Common Is It?
Strongyloidiasis is globally undermeasured because infection is often silent, larval output is intermittent, routine stool techniques have poor sensitivity, and surveillance is inconsistent. WHO's 2024 guideline cites an estimated 300-600 million infections worldwide, while emphasising uncertainty. Tropical and subtropical settings carry the largest recognised burden, but transmission also occurs in temperate foci. A person may present many years after leaving an endemic area because autoinfection maintains infection without new environmental exposure. Prevalence estimates based only on a single direct stool smear or Kato-Katz examination are likely to be substantial underestimates.
India has ecological conditions compatible with transmission and published cases from multiple regions, yet this guide does not present a single national prevalence percentage. Available studies differ in population, geography and assay, and routine deworming data cannot be assumed to measure Strongyloides because albendazole programmes aimed at other soil-transmitted helminths and insensitive microscopy may miss it. Local prevalence should therefore be reported with the test method, denominator and population rather than extrapolated to the country.
The clinical burden is also concentrated unevenly. People receiving corticosteroids, patients with haematological malignancy, transplant recipients and those with HTLV-1 may be disproportionately represented among catastrophic presentations even if their underlying infection was previously mild. CDC notes that HIV alone has not shown the same consistent association with hyperinfection in observational studies. Hospital case series over-represent severe disease, while community surveys reveal otherwise unrecognised infection. These biases mean that neither a low local case count nor absence of symptoms makes pre-immunosuppression risk negligible.
Risk Factors
Acquisition risk begins with bare-skin contact with faecally contaminated soil where sanitation permits larvae to develop. Relevant histories include birth, residence, military service, agricultural work, mining, institutional living or prolonged travel in tropical or subtropical areas. Walking barefoot, inadequate disposal of human waste and repeated occupational soil exposure increase opportunity for skin penetration. Exposure may be remote: limiting questions to recent travel defeats the purpose of screening because untreated autoinfection can sustain infection for decades. Household proximity alone does not usually transmit infection directly; environmental contamination is the important link.
Risk of hyperinfection is a separate question from risk of acquisition. Corticosteroids are the clearest precipitant and severe disease has followed courses given for asthma, COPD, autoimmune disease, cerebral oedema and other indications. Do not assume that a brief course or a particular route is safe. Other high-risk settings include HTLV-1 infection, leukaemia or lymphoma, cytotoxic chemotherapy, organ transplantation and selected immunomodulators. Malnutrition and impaired host defences may increase concern, but evidence is less uniform. HIV infection can coexist with severe disease, although CDC states that observational evidence has not shown a consistent excess risk comparable with corticosteroids or HTLV-1.
Screening priority rises when exposure history intersects with planned corticosteroids, transplantation, haematological cancer treatment or unexplained eosinophilia. An absent eosinophil rise does not lower risk reliably in an immunosuppressed or critically ill patient. In an internationally mobile patient, ivermectin safety also requires asking about residence in Loa loa-endemic parts of Central or West Africa because high microfilarial loads can create a risk of ivermectin-associated encephalopathy. Pregnancy, breastfeeding, body weight below 15 kg, drug availability and inability to absorb oral medication affect treatment planning rather than acquisition.
Diagnosis
History
Ask about the whole lifetime geography of residence and soil contact, not only the last journey. Elicit intermittent diarrhoea, constipation, abdominal pain, nausea, weight loss, cough, wheeze, recurrent urticaria and the speed and distribution of a moving rash. Record previous eosinophilia and deworming, while recognising that routine albendazole exposure does not prove eradication. Establish the exact immunosuppressive drugs, dates and urgency of future therapy; ask about transplant, malignancy and HTLV-1. In acute deterioration, look for fever, dyspnoea, haemoptysis, gastrointestinal bleeding, ileus, confusion and symptoms of sepsis or meningitis.
Examination
Assess hydration, nutrition, temperature, haemodynamics, oxygenation and mental state. Inspect trunk, buttocks and thighs for rapidly migrating larva currens, and feet for penetration sites or secondary infection. Examine for wheeze, crackles, respiratory distress, abdominal tenderness, distension, peritonism, bleeding and features of ileus. Seek signs of meningism or focal neurological dysfunction. The examination may be normal in chronic infection, and no individual physical sign excludes it.
Investigations
Obtain a full blood count with differential, but never use a normal eosinophil count to exclude hyperinfection. Strongyloides IgG is useful for screening, subject to cross-reactivity and reduced sensitivity in immunosuppression; antibodies may remain after cure. Direct stool microscopy is insensitive when used once. Request serial samples and a sensitive method such as Baermann concentration or agar-plate culture where available; PCR performance varies by assay. Larvae in stool establish infection. In suspected hyperinfection, urgently examine stool and respiratory specimens, including sputum or bronchoalveolar fluid when clinically indicated, and culture blood and cerebrospinal fluid as appropriate for enteric bacterial infection. Investigate organ dysfunction and image the chest or abdomen according to the syndrome. Do not wait for every result before escalating a critically ill patient.
Differential Diagnosis
Chronic gastrointestinal symptoms are nonspecific. Consider giardiasis, amoebiasis, bacterial or protozoal infection, coeliac disease, inflammatory bowel disease, pancreatic insufficiency, medication effects and functional bowel disorders. Hookworm, Ascaris, schistosomiasis, filarial infection and other helminths may cause eosinophilia or positive cross-reacting serology. Hookworm ova rather than Strongyloides larvae are usually identified in stool. Cutaneous larva migrans tends to advance more slowly and usually follows a local exposure pattern, whereas larva currens can move rapidly and recur around the buttocks, perineum or trunk. Scabies, urticaria and contact dermatitis remain common mimics.
Pulmonary symptoms with eosinophilia raise asthma, allergic bronchopulmonary aspergillosis, eosinophilic pneumonia, drug reaction and other parasite migration syndromes. In an immunosuppressed patient with bilateral infiltrates, distinguish hyperinfection from bacterial pneumonia, tuberculosis, Pneumocystis jirovecii pneumonia, invasive fungal disease, viral pneumonitis, pulmonary oedema and diffuse alveolar haemorrhage. More than one process may coexist: migrating larvae can carry enteric organisms across damaged mucosa, so Gram-negative pneumonia, bacteraemia and meningitis may be consequences rather than alternative explanations.
Eosinophilia also requires review for atopy, medicines, adrenal insufficiency, vasculitis, clonal haematological disease and other parasites. Conversely, severe strongyloidiasis may have no eosinophilia. A positive antibody result in an endemic setting may reflect current infection, prior infection or cross-reaction and should be interpreted with parasitology, immune status and planned treatment. A negative single stool test is weak contrary evidence. Diagnostic reasoning should classify uncomplicated infection versus hyperinfection or dissemination because urgency, specimens and duration of treatment differ materially.
Management
Treat confirmed strongyloidiasis because spontaneous reliable clearance cannot be expected and later immunosuppression may transform chronic infection. For an uncomplicated immunocompetent adult, CDC's United States clinical guidance lists ivermectin 200 micrograms/kg orally for one or two days as first-line therapy. This regimen should be reconciled with Indian product availability, the patient's weight, pregnancy or lactation, possible Loa loa exposure and local specialist advice. Albendazole is less effective and is an alternative when ivermectin cannot be used; it must not be represented as equivalent merely because it is familiar from mass deworming.
Hyperinfection or disseminated infection requires urgent inpatient infectious-disease and critical-care management. CDC advises ivermectin 200 micrograms/kg orally every day until stool and/or sputum examinations remain negative for two weeks. Reduce or stop immunosuppression if clinically possible through agreement with the treating specialty; abrupt steroid withdrawal may itself be dangerous. Investigate and treat bacterial sepsis or meningitis, support respiratory and gastrointestinal failure, and repeat parasitology to document falling larval burden. Ileus and malabsorption threaten oral exposure. Rectal dosing and veterinary subcutaneous ivermectin have only case-report experience and regulatory constraints; they require expert, pharmacy and regulatory oversight, not improvised substitution.
Before elective immunosuppression, create enough time for exposure assessment, testing, treatment and a follow-up plan. When emergency immunosuppression cannot wait and exposure risk is substantial, specialist-guided presumptive ivermectin may be considered, but the evidence and Loa loa hazard must be addressed. WHO's recommendation for annual single-dose ivermectin mass administration applies to all eligible people aged five years and older in endemic implementation units with measured prevalence at least five percent. It does not define bedside treatment of a symptomatic patient, child under five, pregnant person or hyperinfection case.
Prescribing Information
Verify the current locally authorised ivermectin formulation and calculate from an accurate weight. For uncomplicated infection, the cited CDC regimen is 200 micrograms/kg orally for one or two days; hyperinfection uses the same weight-based daily amount but continues until parasitological clearance criteria are sustained. These regimens are not interchangeable with the WHO population programme schedule. Document indication, immune status, whether infection is uncomplicated, and the tests planned after treatment. Counsel about dizziness, gastrointestinal effects and rash, and review concomitant medicines and hepatic illness.
Confirmed or suspected high-burden Loa loa infection is a relative contraindication because severe neurological reactions can follow rapid microfilarial killing. A relevant exposure history is residence in endemic areas of Central or West Africa, not Indian residence itself. CDC also lists weight below 15 kg and pregnancy or lactation as relative cautions in its US clinical table. Individual maternal treatment balances uncertain fetal or infant risk against the potentially grave risk of untreated infection; population exclusions cannot be copied mechanically into emergency clinical care. Obtain paediatric, obstetric or tropical-medicine advice where appropriate.
Albendazole 400 mg twice daily for seven days is the CDC-listed alternative, with lower efficacy than ivermectin. Avoid the first trimester unless expert risk-benefit assessment supports treatment, review hepatic risk and hypersensitivity, and do not assume previous single-dose deworming cured Strongyloides. Prolonged or repeated antiparasitic exposure may require laboratory monitoring according to product information and clinical state. In hyperinfection, antimicrobial therapy targets documented or strongly suspected enteric bacterial translocation; ivermectin does not replace sepsis treatment. Never prescribe corticosteroids for rash or wheeze in an exposed patient without considering Strongyloides, but do not abruptly stop essential steroids without managing adrenal and disease-specific consequences.
When to Refer
Refer urgently or admit anyone with suspected hyperinfection or dissemination: an at-risk patient with new hypoxaemia, diffuse pulmonary infiltrates, haemoptysis, severe diarrhoea, ileus, gastrointestinal bleeding, sepsis, Gram-negative bacteraemia, meningism or neurological dysfunction. Contact infectious diseases, critical care, microbiology and the specialty responsible for immunosuppression early. Respiratory and stool samples must reach a laboratory able to recognise larvae, and bacterial cultures should not be omitted. If oral absorption is doubtful, a tertiary service is needed because alternative ivermectin routes are nonstandard and may require regulatory access.
Seek specialist advice before urgent corticosteroids, chemotherapy, biologic therapy or transplantation when lifetime exposure is plausible and testing cannot be completed promptly. Referral is also appropriate for HTLV-1 infection, recurrent positive tests, persistent symptoms after therapy, failed serological decline, paediatric weight below 15 kg, pregnancy, breastfeeding, severe liver disease, or possible Loa loa co-infection. A negative routine stool smear should not close the referral when the pre-test probability is high.
Stable uncomplicated infection may be managed by a clinician familiar with antiparasitic therapy if reliable testing, weight-based prescribing and follow-up are available. Escalate when the laboratory offers only insensitive methods or cannot distinguish Strongyloides from hookworm larvae. In India, specify the required capability rather than sending a vague referral: serial parasitology or serology, infectious-disease review, management of immunosuppression, and access to critical care if severe. Communicate the timing of the next immunosuppressive dose and confirm who will review results. Public-health consultation is separate and becomes relevant if population surveys or preventive chemotherapy are contemplated.
Red Flags
The most dangerous pattern is clinical deterioration after corticosteroid exposure in a person who has ever lived in or travelled extensively through an endemic setting. Fever, tachypnoea, hypoxaemia, rapidly progressive bilateral infiltrates, haemoptysis, abdominal distension, ileus, gastrointestinal haemorrhage, shock, confusion or meningism can signify hyperinfection with bacterial translocation. Larvae in sputum or another extraintestinal specimen demand immediate escalation. Do not be reassured by a normal eosinophil count; eosinophilia is often absent in fulminant disease and its disappearance during decline may be ominous rather than curative.
Other high-risk clues include Gram-negative bacteraemia or meningitis without a clear source, recurrent sepsis, unexplained enterocolitis, or simultaneous pulmonary and gastrointestinal disease during immunosuppression. A serpiginous eruption that visibly changes position over hours is an important diagnostic clue. Planned high-dose steroids, haematological cancer therapy or transplantation creates a prevention red flag when there is remote tropical exposure, persistent eosinophilia or unexplained positive serology. The safe response is expedited assessment, not automatic clearance after one negative stool specimen.
Prescribing red flags include ivermectin without checking for Central or West African Loa loa exposure, guessing weight, using a mass-administration dose as a hyperinfection regimen, and giving albendazole as if it were equally effective. Ileus, vomiting or malabsorption may make an apparently correct oral prescription ineffective. Pregnancy, lactation and very low body weight require individual specialist assessment. Failure to obtain negative follow-up specimens in severe disease, ongoing immunosuppression and continued larval detection all signal that treatment cannot stop. Give explicit return instructions and record the emergency service that can receive the patient.
Indian Clinical Context
India combines endemic environmental exposure, large internal migration, variable sanitation, frequent empirical deworming and uneven access to Strongyloides serology, culture and PCR. These realities can produce both underdiagnosis and false reassurance. A laboratory report saying stool examination negative may reflect a single direct smear rather than Baermann concentration, agar-plate culture or repeated sampling. Clinicians should ask what method was actually used. Similarly, a history of school or community albendazole does not establish Strongyloides cure because programmes aimed at other soil-transmitted helminths use regimens that are not the preferred individual therapy here.
No current national Indian patient-level strongyloidiasis treatment guideline was verified for this draft. The CDC sources are US clinical guidance; their drug availability statements, regulatory route for subcutaneous veterinary ivermectin and pregnancy labels are not automatically Indian policy. WHO's 2024 document is global public-health guidance recommending annual community ivermectin only in eligible endemic areas with measured prevalence at least five percent. India should not be labelled an implementation unit, and an individual should not receive mass treatment, without current national or state programme authority and the required epidemiological assessment.
Practical prevention includes footwear and sanitation, but counselling must avoid blaming people who cannot control occupational exposure or infrastructure. The immediate Indian safety opportunity is a pre-immunosuppression checkpoint: lifetime geography, eosinophil history, appropriate testing, treatment when indicated, and clear documentation before steroids, oncology regimens or transplantation. When a diagnostic service is unavailable, the referring team should contact a capable microbiology or infectious-disease centre rather than repeat insensitive tests. Drug procurement, unlicensed routes and critical-care transfer require institutional processes. This quarantined educational draft supports reasoning; it does not replace examination, current local product information or organizational clinical approval.
NMC Competency Mapping
Strongyloidiasis integrates microbiology, pathology, pharmacology, internal medicine, community medicine and emergency care. The Indian medical graduate should explain the free-living and parasitic phases, skin penetration, pulmonary migration, adult intestinal stage and autoinfection. They should distinguish rhabditiform diagnostic larvae from infective filariform larvae, relate autoinfection to lifelong persistence, and connect corticosteroid-impaired cellular defence with hyperinfection, bacterial translocation and dissemination. Exact competency codes and wording must be verified against the current 2024 NMC curriculum before formal timetable, logbook or assessment mapping is published.
At the bedside, learners should take a lifetime exposure and immunosuppression history, recognise larva currens, assess gastrointestinal and respiratory severity, and interpret eosinophilia without treating it as an exclusion test. Laboratory learning includes why one direct stool smear is insensitive, the role of serial specimens, Baermann concentration, agar culture, serology and selected molecular tests, and safe handling of potentially infectious stool. Students should construct differentials for eosinophilia, chronic diarrhoea and sepsis, and identify the intersection of a tropical infection with routine steroid prescribing.
Prescribing competence is bounded. Remembering ivermectin 200 micrograms/kg does not authorise treatment without weight, syndrome classification, pregnancy assessment, Loa loa history, absorption review and follow-up. Learners must separate uncomplicated treatment, daily emergency therapy for hyperinfection and WHO population preventive chemotherapy. Simulation can assess urgent handover of an immunosuppressed patient with pulmonary and gastrointestinal decline. Appropriate performance includes cultures, supportive priorities and consultation, not merely naming the parasite. Undergraduate learning does not confer competence to use non-oral veterinary formulations, manage transplantation immunosuppression or declare parasitological cure without supervision.
Key Exam Pearls for NEET PG
Strongyloides stercoralis is unusual among intestinal nematodes because autoinfection can amplify infection within one host and permit persistence for decades. Infective filariform larvae penetrate skin; adult parthenogenetic females reside in small-intestinal mucosa; rhabditiform larvae usually pass in stool. Larvae, rather than typical helminth eggs, are the key routine parasitological finding. Internal and external autoinfection distinguish the lifecycle and explain why remote exposure remains relevant. Larva currens is a rapidly moving, recurrent, serpiginous urticarial track, commonly over buttocks, perineum or thighs.
Uncomplicated disease may be silent or cause abdominal pain, fluctuating diarrhoea and constipation, cough, wheeze and eosinophilia. A single stool examination has low sensitivity because larval shedding is sparse and intermittent. Serial samples with Baermann or agar-plate culture improve detection; serology is useful for screening but may cross-react and may not distinguish past from current infection. Eosinophilia supports chronic infection but is commonly absent in hyperinfection.
Corticosteroids, HTLV-1, haematological malignancy and transplantation are high-yield risks for severe disease. Hyperinfection increases larvae along the gut-lung route; dissemination reaches organs outside it. Enteric bacteria may accompany larvae, producing Gram-negative sepsis or meningitis. Ivermectin is preferred for uncomplicated infection; severe disease requires daily ivermectin until stool or sputum remains negative for two weeks, plus reduction of immunosuppression when possible and treatment of bacterial complications. Loa loa exposure is a safety check before ivermectin. WHO's five-percent threshold concerns annual community preventive chemotherapy, not diagnostic probability or an individual treatment threshold.
Frequently Asked Questions
Can Strongyloides infection still matter decades after leaving an endemic area?
Yes. Autoinfection allows S. stercoralis to complete repeated cycles within the same host, so untreated infection can persist for decades without a new soil exposure. A lifetime residence and travel history is therefore essential before corticosteroids, transplantation or other major immunosuppression.
Does a normal eosinophil count or one negative stool test rule out strongyloidiasis?
No. Eosinophilia is inconsistent and may be absent in hyperinfection. Larval output is intermittent, so one routine stool examination is insensitive. Screening and diagnosis may require serology plus serial stool specimens examined with a sensitive concentration or culture method, interpreted in the clinical context.
Why should Strongyloides be considered before prescribing corticosteroids to a patient?
Corticosteroids can accelerate autoinfection and precipitate hyperinfection or dissemination from a previously silent infection. This can cause respiratory failure, enterocolitis and enteric Gram-negative sepsis or meningitis. Exposure assessment, suitable testing and treatment when indicated should precede elective immunosuppression, with urgent specialist planning when steroid therapy cannot safely wait.
Is the WHO community ivermectin recommendation the same as treating a patient?
No. WHO's 2024 recommendation concerns annual preventive chemotherapy for eligible populations aged five years and older in endemic implementation units with measured prevalence at least five percent. Individual uncomplicated infection, pregnancy, low body weight and hyperinfection require patient-specific clinical regimens and safety assessment.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic